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In the twilight of the 20th century, Jeremy Rifkin’s The Biotech Century (1998)2 and 
Richard Oliver’s The Biotech Age (2003)3 expressed mixed feelings about the 
prospect of capital expansion through biotechnological innovation. The former was 
terrified while the latter was excited about this prospect.4 Twelve years into the 21st 
century, the question that arises is, what is the actual relationship between the life 
sciences and the market? Rajan’s collection of essays addresses this question by 
bringing together cultural anthropology and science and technology studies.  
 
The book begins with the editor’s introduction, arguing that there are certain overlaps 
between the development of life science epistemologies and the epistemologies of 
neo-liberal economics. The latter consists of value systems which are distinct from 
those Marx traced during the first industrial revolution. Rajan points out that in the era 
of life sciences innovation the ‘magic of capital’ lies not in the creation and 
appropriation of surplus through exchange but in the creation and appropriation of 
‘the new thing’. This is what he calls lively capital. However, drawing on the recent 
work of Laurence Reynolds and Bronislaw Szerszynski,5 one might question the 
existence of lively capital on the grounds that biotechnology has never become a ‘lead 
industry’ in the way that steam power or electricity did in the early period of capitalist 
expansion. Indeed, as Reynolds and Szerszynski claim:  
 
…fundamental to the period of renewed capitalist growth around the 
closing decade of the twentieth century was a r elatively ‘low tech’ 
ensemble of cranes, d iesel engines, containers, ships and logistical 
information technologies, not the spawn of the ‘high-tech’ R&D labs 
of the ‘knowledge-based economy. 6 
 
This claim, of course, does not imply that there is no co-production of life and capital. 
Rather it implies that new life science technologies have not yet revolutionised the 
means of production.  
 
Rajan’s book tries to understand the co-production of life and capital in the 21st 
century. In order to do so, it is divided into four parts. Part I is entitled ‘encountering 
value’ and includes three chapters on valuing illness, dogs and air. In chapter 1, 
Joseph Dumit criticises clinical trials, screening programmes and other data collection 
tools which are used in the propaganda for the increased use of drugs. In his view it is 
illness as value that is now being maximised, and the health of patients. This view is 
confirmed by recent research that suggests pharmaceutical companies increase profits 
from selling new drugs with minor clinical advantages over existing treatments. 7 
Therefore they do not depend on research breakthroughs. Dumit correctly argues that, 
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in fact, the capitalist logic that Marx studied is mirrored by the strategies of 
pharmaceutical executives and marketers. In chapter 2, Donna Haraway takes this 
argument further by examining companion-species kin patterns of consumerism. 
According to her, there is an increase in the availability of treatments and health 
insurance for pets. Today’s lively capital practices are reflected in this particular 
phenomenon of consumerism. In chapter 3, Timothy Choy examines the quality of air 
in cities such as Hong Kong. This chapter is very interesting; Choy considers various 
health issues, stressing that stratification of air spaces in Hong Kong have been tied to 
income and occupations.  
 
Part II is probably the most important part of the book because it focuses on property 
and dispossession,  key elements of capital expansion. In chapter 4, Sheila Jasanoff 
opens the discussion by raising one crucial question: when does something in nature 
become property? To answer this question, she explains the logic of Western legal 
systems, emphasising their utilitarian character:  
 
no private use, the law imagines, could possibly outweigh the public 
benefit of a nature whose works and workings rem ain available in 
equal measure, to everyone (p.158).  
 
In order for an inventor to claim an IPR on a natural object, he/she has to change the 
quality of the object itself. Jasanoff is critical of specific IPRs such as patents that 
confer temporary monopoly to the holder contrary to the spirit of free competition. 
Her criticism is based on analysis of several cases, including the landmark court 
decision of Diamond v. Charkabarty in 1980 that enabled the extension of the 
appropriation of life sciences as intellectual property. In chapter 5, Elta Smith 
continues the topic of IPRs in genomics, examining rice genomes sequenced by public 
and private consortiums. In this context, she introduces the notion “hybrid properties” 
to describe the “bundles of rights” that range between fully protected private property 
and a completely accessible public domain. According to Smith:   
 
“Hybrid properties” in genomic information represent a set o f social 
classifications that have devel oped alongside the pr oduction of new 
scientific knowledge. In sharp contrast to traditional conceptions of 
the relations between science and law where knowledge generation 
is seen as separate from rule m aking, my account suggests that 
representations of the genom e come into being with tacit prope rty 
regimes attached to them. Thus property rights for biotechnology are 
emerging, not only in f ormal, top-down institutional processes such 
as patents suits, regulatory frameworks, or multi-lateral treaties and 
trade agreements, but also at diverse sites in the every day practices 
of genome research. (p.187).     
 
Although Smith does not clarify whether she is concerned with IPRs as moral or legal 
rights, she concludes that different factors, including national interests, scientific 
norms and profitability, affect the way genome research is transformed into private 
property. In chapter 6, Travis Tanner moves on to discuss dispossession. The 
discussion is focused on two examples: an ongoing struggle for land rights and an 
incident of genetic theft that occurred in 1991 in Wellington Public Hospital in New 
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Zealand. Both examples come from a novel written by Patricia Grace, an indigenous 
writer from New Zealand. The examples are analysed in the light of Marx’s critique 
of dispossession as a capitalist phenomenon with economic and cultural effects. In 
chapter 7, Kristin Peterson concludes this part of the book by discussing wealth 
accumulation and dispossession in Africa. This is the only chapter that focuses on a 
developing continent. Peterson analyses wealth extraction and dispossession as 
providing the ground in which competing kinds of capital find their roots and growth. 
She specifically draws on the case of Nigeria, arguing that the primary source of 
accumulation is not wage labour but government contracts and oil rent politics. In 
Nigeria, since the IMF structural adjustment, there has been a decline in drug 
manufacturing. Peterson looks at the excess of counter-freights, illegal drug markets, 
self-medication, and drug labelling problems as produced materiality and practice.    
 
Part III focuses on global knowledge formations. In chapter 8, Andrew Lakoff 
combines ethnography and politics to analyse the case of a French company that tries 
to find genes linked to psychiatric illness among a group of Argentine patients. He 
makes the crucial point that lack of regulation in countries such as Argentina leave 
patients open to abuses of transnational genomics research. In chapter 9, Wen-Hua 
Kuo discusses the harmonisation of regulatory regimes. He shows how the world of 
pharmaceuticals itself formulates operational standards. His approach is both 
institutional and transnational. Kuo focuses on the case of the International Conference 
for Harmonisation (ICH). He analyses the issue of acceptability of foreign clinical 
data through comparison of three countries: Japan, Taiwan and Singapore. In chapter 
10, Kim Fortun shifts focus from international to national, discussing biopolitics and 
informatic environmentalism. She is particularly interested in ‘chemical security’ 
arguing that in countries such as the United States, this notion of security has become 
the justification for withdrawing environmental risk information from the public 
domain. 
 
Part IV, the concluding part of this book, is entitled ‘promissory experiments and 
emergent forms of life’. In chapter 11, Mike Fortun discusses the role of promise in 
the multiple scientific, legal, political and cultural contexts. In his view: 
 
genomics can’t avoid playing beyond its means (p.334).  
 
The performativity of promises can be seen in a number of examples, including 
deCode Genetics in Iceland. In chapter 10, Chloe Silverman focuses on the promise of 
new life sciences to treat autism and its symptoms. She calls attention to parents’ 
movement on biomedical interventions for autism spectrum disorders. In chapter 13, 
Michael M. J. Fischer examines lively biotech and translational research. He argues 
that lively capital might be understood to include at least four kinds of capital: 
venture; corporate or government; intellectual; and symbolic and scientific. In his 
view, all these forms of capital are bankable and play a crucial role in bio-capitalism.  
 
In the epilogue Rajan undertakes to thread together the variety of chapters and 
disciplines presented. This is a rather difficult task, given the lack of central narrative 
throughout the chapters. Rajan is aware of this difficulty and therefore he stresses that 
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his aim is not to create a unifying framework but rather to highlight specific points of 
convergence, divergence and distinction. These points concern empirical 
methodological and political questions. Although the contributors to this book address 
such questions differently, Rajan’s conclusion is clear: the history and promise of life 
sciences are heavily over-determined by systems and logics of capital.  
 
This book, despite its lack of central narrative and/or unifying framework, is an 
important collection of essays in the field of ethics and governance of new life  
sciences innovation, and deserves to be read by sociologists, ethicists, cultural  
anthropologists, and all those who work in this field.    
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